Home / Health / Gut Health Supplements Pair With Weight Loss Drugs
Gut Health Supplements Pair With Weight Loss Drugs
20 Aug
Summary
- Research to explore microbiome supplements' benefits alongside GLP-1 drugs.
- Results from gut health and weight-loss drug research expected in 2027.
- Companies seek to develop products for users of booming obesity drugs.
Novonesis expects research outcomes in the second half of 2027 regarding the efficacy of microbiome supplements when used with GLP-1 weight-loss drugs. This collaborative effort with Novo Nordisk is investigating how gut health solutions can provide supplementary benefits to individuals taking GLP-1-based medicines.
The partnership, initially focused on improving metabolic health, has now shifted to exploring the synergistic effects of synbiotic supplements—a blend of probiotics and prebiotics—alongside GLP-1 medications. Research will assess impacts on blood glucose, cholesterol, and gut microbiome biomarkers.
This initiative aligns with the booming obesity market, where pharmaceutical companies like Novo Nordisk and Eli Lilly are prominent. Novonesis, leveraging its expertise in microorganisms and probiotics, aims to develop tailored nutrition products for the growing number of patients using weight-loss drugs.
